Back to trial details

Intake questionnaire

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Applying to University of Chicago · Chicago, Illinois

Answer a few short questions to share with the research team.

0 of 3 answered

1. Are you 12 years old or older?
2. Have you been diagnosed with Locally Advanced Solid Tumors?
3. Are you able to travel to Chicago for study visits?